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ABSTRACT: Human pancreatic ductal adenocarcinoma (PDAC)
involves the dysregulation of multiple signaling pathways. A novel
approach to the treatment of PDAC is described, involving the targeting
of cancer genes in PDAC pathways having over-representation of G-
quadruplexes, using the trisubstituted naphthalene diimide quadruplex-
binding compound 2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-
yl)ethyl)amino)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tet-
raone (CM03). This compound has been designed by computer
modeling, is a potent inhibitor of cell growth in PDAC cell lines, and has
anticancer activity in PDAC models, with a superior profile compared to
gemcitabine, a commonly used therapy. Whole-transcriptome RNA-seq
methodology has been used to analyze the effects of this quadruplex-
binding small molecule on global gene expression. This has revealed the
down-regulation of a large number of genes, rich in putative quadruplex
elements and involved in essential pathways of PDAC survival, metastasis, and drug resistance. The changes produced by CM03
represent a global response to the complexity of human PDAC and may be applicable to other currently hard-to-treat cancers.
■ INTRODUCTION
Pancreatic cancer remains one of the most difficult to treat
human cancers.1 Pancreatic ductal adenocarcinomas (PDACs)
comprise some 85% of diagnosed cases and are classified into
several subtypes on the basis of expression analysis of major
mutated genes.2 PDACs typically have extensive patterns of
germline mutations, especially in DNA repair and signaling
pathways.3,4 The most common mutations in PDACs are in the
KRAS, TP53, SMAD4, and CDKN2A genes, with a lower
frequency of mutations in many other genes.3−6 A feature of
PDACs is the distinctive pattern of changes in several gene
pathways such as those involved in axon guidance and
dysregulation of signal transduction via inhibition of Rho-
GTPases.6,7
Only <4% of those diagnosed with stage III of PDAC survive
for more than five years,8,9 a situation that has not significantly
changed for more than 40 years. Surgery is an option for <15−
20% of cases, and chemotherapy for locally advanced
inoperable or metastatic disease is still largely palliative. The
nucleoside analogue gemcitabine remains a widely used
monotherapy regimen used to treat PDAC.10 Various
formulations of gemcitabine and combinations with, in
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particular, paclitaxel, have been developed; some have been in
clinical trial,11 and a small number have received regulatory
approval1 but their benefit is limited. The use of combination
regimens of cytotoxic agents, as in the FOLFIRINOX (folinic
acid + irinotecan + 5-fluorouracil + oxaliplatin) combination,12
is restricted in use due to their toxicity. By contrast to other
cancers, immunotherapy has not shown promising clinical
results with PDAC,1 possibly due to its inherent immunosup-
pression. Therapies based on the common mutations in
pancreatic cancer that target hard-to-drug proteins such as
KRAS have not yet reached the clinic, although recent results
suggest promise for the future.13
Here, we report an alternative approach, of selectively
targeting G-quadruplex (G4) elements in the genomes of
pancreatic cancer cells. The human genome contains a large
number of putative G4 sequences comprising several (typically
four) short guanine tracts separated by more general sequence
loops (reviewed in ref 14). G4 sequences are over-represented
in promoters15 and untranslated regions, particularly in genes
associated with cell proliferation and cancer.16,17 In principle,
this over-representation in cancer-associated genes gives G4
targeting a therapeutic advantage, which can be emphasized by
stabilizing individual G4 structures with an appropriate G4-
selective small molecule. Visualization of G4s in cancer cells18,19
and tissues20 has further demonstrated their potential for
selectivity. Many studies have examined the effects of such
compounds on G4s within individual target genes,21 arising
from the concept that stabilization of a promoter G4 can result
Figure 1. G4 modeling, FRET, and cell line growth inhibition studies of the trisubstituted naphthalene diimide derivatives MM41 and CM03. (a)
MM41 structure and (b) molecular model of MM41 bound to a human telomeric G4, following docking and minimization and using the co-crystal
structure (PDB 3UYH)32a as a starting point. The red dotted circle highlights the fourth pyrrolidino side chain substituent of MM41, which is not
buried in a G4 groove, by contrast with the other three side chains. (c) CM03 structure and (d) molecular model of CM03 bound to the native
parallel human telomeric G4 structure (PDB 1KF1)32b following docking and minimization. MM41 and CM03 are shown in ball-and-stick
representation and the G4 in surface representation, with electrostatic interaction regions colored yellow. (e) Table showing melting temperature
changes (ΔTm) in °C, for CM03 and MM41 with a panel of G4s, determined using a FRET procedure performed in solution containing 50 mM K+
ion. Ligands were used at 1 μM concentration. Standard deviations are from triplicate measurements. (f) Growth inhibition assays. Short-term 96 h
IC50 values (in nM) for the two compounds in cancer and normal fibroblast cell line panel. Average growth inhibition is shown with standard
deviations from >3 individual determinations.
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in inhibition of the expression of the gene involved.22 A wide
range of chemotypes as G4 stabilizers have been examined
although they tend to share common structural features of an
extended aromatic or heteroaromatic core with one or more
cationic side chains.21 Down-regulation of “targeted” genes
such as MYC, KIT, BCL2, VEGF, and KRAS has often been
reported (reviewed in ref 23), although unequivocal demon-
strations of direct cause and effect at the cellular level have
rarely been made.24 The synthetic fluoroquinolone compound
Quarfloxin (CX-3543)25 has been evaluated in human cancer
clinical trials, and its G4-binding was reported as inhibiting
RNA biogenesis. More recently, another fluoroquinolone, CX-
5461,26 has been shown to be a G4-binding compound with
selective effects in BRCA1/2-deficient cells; CX-5461 has
recently entered clinical trials for patients with BRCA-deficient
tumors.27
We have adopted a distinct approach in comparison to the
single G4 promoter targeting strategy, in which we have not a
priore assumed any particular promoter G4 targets. Instead, we
have used global genome transcriptome profiling to determine
which genes are affected by a rationally designed G4-binding
small molecule. This has enabled us to determine potential
targets at the whole genome level in two pancreatic cancer cell
lines. We find that pancreatic cancer cell growth is especially
sensitive to CM03 and that it strikingly inhibits tumor growth
in PDAC animal models.
Naphthalene diimides are a favored chemotype for G4
binding because of their high target affinity, synthetic
accessibility, and potential for chemical variability.28,29 We
have previously disclosed several focused libraries of naph-
thalene diimides, in particular, tetra-substituted analogue-
s30,31,32a,33 (Figure 1a) with molecular design based on
crystallographic data for a series of G4−ligand complexes.32a
We report here on a new lead compound, 2,7-bis(3-
morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)benzo-
[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (CM03,
633.34 Da; compound 4 in Scheme 1 and Figure 1c), which
contains two side chains terminating in morpholino groups, a
third side chain terminating in a protonated pyrrolidino group,
and a lower molecular weight compared to the parent tetra-
substituted compound MM4132a (831.08 Da; Figure 1a). We
report here that CM03 (i) has potent growth inhibitory activity
in vitro for pancreatic cancer cells, (ii) has antitumor activity in
vivo in PDAC animal models, (iii) down-regulates the
expression of key genes involved in maintaining the progression
of PDAC and in drug resistance, and (iv) targets genes which
have high G4 propensity.
Altogether these results demonstrate that G4 targeting is a
realistic and attainable concept for potent G4-binding
compounds, and has promise to lead to significant therapeutic
advantage in the treatment of PDAC.
■ RESULTS
Design and Synthesis of the Trisubstituted Naph-
thalene Diimide Compound. The starting-point for CM03
design was the co-crystal structure of MM41 (Figure 1a,b), with
an intramolecular human telomeric parallel G4. We reasoned
that although the nature and structures of most potential target
G4s are unknown, several features are common to all G4s, in
particular a core of stacked G-quartets with small-molecule
binding at one end of the core, as observed in all such NMR
and crystal structures to date. These crystal and docked
structures revealed that the chromophore of MM41 is bound
slightly asymmetrically onto the terminal G-quartet. Con-
sequently, although three out of four of the substituent chains
are each well positioned at the mouth of a G4 groove, the
fourth is not. This is due to the limited surface area of the
naphthalene diimide chromophore, so that the fourth side chain
cannot make effective contacts with a G4 groove and is
oriented away from the G4 surface (Figure 1b), consequently,
its contribution to overall binding is minimal. We hypothesized
that a naphthalene diimide with three substituents would bind
with similar affinity and has the advantage of lower molecular
weight and reduced overall cationic charge. CM03 (Figure 1c)
was therefore conceived and is the subject of the studies
reported here. Docking with MM41 and CM03 reveals that the
poses for the resulting G4 complexes are similar, even though
the CM03 side chains can access only three grooves, while the
MM41 targets all four. CM03 is predicted to have each side
chain positioned at the mouth of a quadruplex groove (Figure
1d). The aromatic chromophore is positioned slightly off-center
because the side chains are not long enough to interact
symmetrically in each groove. The two morpholino side chains
serve to maximize the binding onto the G-quartet platform.
The synthetic approach to the trisubstituted series adapts
previously published procedures to simplify purification and
increase yields of both intermediates and final compounds
(Scheme 1). 5,5-Dimethyl-1,3-dibromohydantoin was used for
the regioselective bromination of the starting material, enabling
more efficient and convenient purification. The separation of
final products was achieved using column chromatography,
giving a 26% overall yield for CM03. It has been formulated as a
highly stable mixed chloride/formate salt (pH 6.9), freely
soluble in water and saline (>10 mg/mL).
CM03 Shows in Vitro G4 Binding Together with
Selective and Potent Antiproliferative Activity. CM03
and MM41 were evaluated for their ability to stabilize G4
binding by means of a fluorescence resonance energy transfer
(FRET) protocol using a FAM/TAMRA donor/acceptor
combination to measure the temperature (Tm) of the helix−
coil transition on gradual heating. A human telomeric G4
Scheme 1. Synthesis of Compound CM03 (4)a
a(i) 5,5-Dimethyl-1,3-dibromohydantoin, H2SO4, 80° C, 72 h; (ii) 3-
morpholinopropylamine, acetic acid, microwave, 130 °C, 25 min (The
intermediate 3b was not isolated); (iii) amine, NMP, microwave, 125
°C, 30 min. For CM03, n = 2, R = pyrrolidino. The overall yield of the
synthesis for steps i to iii (compound 4: CM03) was 26%. The yield
for steps i and ii (from compound 1 to compound 3a) was 35%; the
yield for final step (iii) (compound 3a to compound 4 (CM03)) was
75%.
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sequence (F21T), together with promoter G4 sequences (from
the HSP90, BCL-2, and KRAS genes), and a duplex control (T
loop) were screened against the two compounds (Figure 1e).
CM03 shows a consistent pattern of ∼2-fold (range 1.98−2.25)
lower melting stabilization temperature (ΔTm) compared to
MM41 for all tested G4s. The pattern of differences in ΔTm
values between individual G4s is closely similar between the
two compounds. Duplex DNA stabilization is significantly
reduced for CM03 compared to MM41.
Quantitative binding estimates as KD values were obtained
from fluorescence anisotropy titrations (MM41) and direct
fluorescence titrations (CM03). The DNA human telomeric
G4 sequence 5′-d(GGGTTAGGGTTAGGGTTAGGG)-3′
was used to enable direct comparisons to be made with the
modeling studies. Both compounds bind with nanomolar
affinity to this DNA G4, with a ∼3-fold difference between
MM41 (20 ± 2 nM) and CM03 (67 ± 4 nM).
Compounds were screened with a 96 h SRB (sulforhodamine
B) assay for their antiproliferative activity in a panel of human
Figure 2. CM03 treatment reduces tumor volume in a MIA PaCa-2 xenograft model of PDAC. (a) Plot showing the tumor volume of MIA PaCa-2
xenografts treated with CM03, MM41, gemcitabine, or saline (control) over 62 days. There are eight CD-1 mice per condition and dosing for all
cohorts was stopped on day 28, shown by the red arrow. Standard error of the mean (SEM) is indicated for all growth curves for each tumor volume.
* p < 0.05, ** p < 0.01, *** p < 0.001 (Student t test). (b) A plot of weight for the eight mice in the 15 mg/kg CM03 cohort of this xenograft
experiment, for the first 40 days of the experiment. (c) Table showing changes in tumor volume (TV), in cm3, relative to the control cohort at the
selected three time points (MTV represents mean tumor volume). Statistical analysis between the average tumor volume of treated versus control
mice cohorts at the given time points was performed using the Student t test * p < 0.05, ** p < 0.01, *** p < 0.001. (d) Sections of hematoxylin and
eosin-stained organ tissue, taken from animals at the termination of the xenograft experiment. In each case, images from a single animal are shown.
No differences between animals in a cohort were observed. Sections through (i) kidneys and (ii) livers taken from a control (untreated) and a
CM03-treated mouse. (e) (i) IVIS images of a saline (control) untreated mouse and a 10 mg/kg CM03 treated mouse with tumors on their flank, 4
h after administration; (ii) IVIS images of the excised tumor from each animal (untreated control and 10 mg/kg CM03 treated) 4 h after
administration. (f) Kaplan−Meier plot showing survival of PDAC-bearing KPC mice post onset of treatment (CM03, n = 7, control, n = 5, Mann−
Whitney, p = 0.217).
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cancer cell lines comprising lung adenocarcinoma (A549),
breast adenocarcinoma (MCF7), and PDAC (MIA PaCa-2 and
PANC-1) cell lines, as well as a fetal lung fibroblast-like
nononcogenic control cell line (WI-38) (Figure 1f). Both
compounds show highly potent growth inhibition activity,
particularly for the lung and pancreatic cancer cell lines, which
are responsive at low nM concentrations. The responses are
highly cell-line-dependent; CM03 shows >20-fold selectivity for
Figure 3. Differentially down-regulated genes common to both PANC-1 and MIA PaCa-2 are enriched in PQs after treatment with 400 nM CM03.
(a,b) MIA PaCa-2 and PANC-1 cells were treated with 400 nM CM03 for 6 and 24 h and mRNA extracted for analysis by RNA-Seq. Genes were
split into four subgroups according to their fold change upon CM03 treatment versus untreated: Down (Log2 FC < 0.5, FDR < 0.1), Up (Log2 FC >
0.5, FDR < 0.1), Down strong (Log2 FC ≤ 1.0, FDR < 0.05) and Up strong (Log2 FC ≥ 1.0, FDR < 0.05) and analyzed for PQs occurrence in both
(a) promoter (100 bp downstream and 2 kb upstream of the TSS) and (b) gene bodies (exons and introns). See Supporting Information, Table 3
for median and IQR for box and whisker plots. Significance between differentially deregulated gene sets was calculated using the Wilcox statistical
test via R software. *p < 0.05, ** p < 1 × 10−10, *** p < 1 × 10−25. PQs mean number is significantly lower (red asterisks) or higher (black asterisks)
than the no differential expression group (NO). (c,d) enriched KEGG pathways (p < 0.05 with Bonferroni correction) and associated down-
regulated genes (Log2 FC < 0.5, FDR < 0.1) common to both PANC-1 and MIA PaCa-2 cell lines after (c) 6 h and (d) 24 h CM03 treatment using
the ClueGO Cytoscape App. (e) Scatter plot of significant down-regulated KEGG pathways (p-EASE ≤ 0.05) upon 6 and 24 h CM03 treatment.
(f,g) Common (f) down-regulated KEGG pathways after 6 h CM03 treatment are also enriched in promoter and gene body PQs compared to (g)
common-up regulated KEGG pathways at 6 h. The significance threshold of 0.05 is represented by the dotted line on the graph.
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MIA PaCa-2 compared to MCF-7 cells. CM03 also shows
greater selectivity than MM41 relative to the nononcogenic
control fibroblasts (e.g., ∼170-fold vs ∼21-fold for MIA PaCa-2
cells compared to WI-38 cells for CM03 vs MM41,
respectively). CM03 was further examined in additional
pancreatic adenocarcinoma cell lines (CAPAN-1 and BX-
PC3) and again showed low nM activity (IC50 16 ± 4 and 19 ±
4 nM, respectively). Gemcitabine is also active in these lines at
low nanomolar levels, although less so in MIA PaCa-2 (IC50 19
± 5 nM) and more so in BX-PC3 cells (6 ± 2 nM). Taken
together, these results show that CM03 has very potent growth
inhibitory activity in cancer versus “normal” cells, particularly
for PDAC cells.
CM03 Has in Vivo Antitumor Activity. To determine if
the in vitro activity of CM03 was paralleled in vivo, we explored
the activity of CM03 in a mouse xenograft model of PDAC. We
have previously reported that the maximum tolerated dosage
(MTD) for intravenous (IV) administration of MM41 is 25
mg/kg.33 CM03 was well tolerated, up to a dosage of 45−50
mg/kg, as judged by a dose-escalation MTD study. A
therapeutic schedule of two CM03 intravenous (IV) doses
was explored using a subcutaneous MIA PaCa-2 pancreatic
tumor xenograft model derived from the human cell line used
in the cell growth inhibition studies. A group size of eight CD-1
nude mice was used, and dosing was conducted at 10 and 15
mg/kg, each twice weekly, over a period of 4 weeks (28 days: 8
doses). Two further groups were given either MM41 or
gemcitabine at 15 mg/kg and received the same dose regimen.
Over the course of the experiment, CM03 showed a dose-
dependent antitumor response. At the conclusion of dosing on
day 28, all four therapy groups showed significant tumor
growth inhibition compared to the vehicle control group (p <
0.001) (Figure 2a,c), but notably 15 mg/kg CM03 resulted in
the highest mean decrease in tumor volume (MTV) (−73%).
From day 28 onward, while all treatment groups also showed
significant reduction in MTV compared to the control (p <
0.05), the 15 mg/kg CM03 cohort consistently showed the
greatest therapeutic effect and no tumor regrowth was
observed. Five out of the eight animals had tumor volumes
that shrank to <0.05 cm3 by day 62. No body weight reduction
(Figure 2b) or adverse effects such as tumor ulceration were
observed in this group at any time during the study.
Histopathological analysis of vital organs from control and
CM03-treated animals sacrificed at the end of the experiments
also showed no sign of organ damage (Figure 2d). IVIS
imaging of treated mice was performed by taking account of the
intrinsic fluorescence of CM03. This showed significant
accumulation of CM03 in the tumor xenograft on the flank
of the animal (Figure 2e). Thus, in contrast to MM41 and
gemcitabine, the higher-dose CM03 treatment results in a
statistically significant (p < 0.001) antitumor effect, which
persisted long after dosing had ceased, up to the termination of
the xenograft experiment (62 days).
We also tested the higher dose of CM03 in a genetically
engineered mouse model of PDAC. The KPC (Pdx1-Cre; LSL-
KrasG12D/+; LSL-Trp53R172H/+) mouse model is commonly used
for preclinical PDAC cancer studies as it develops tumors that
exhibit many of the genetic and pathological features of the
human disease, including resistance to chemotherapy.34 Mice
with late-stage disease, characterized by swollen abdomen, loss
of body conditioning, and palpable tumor, were treated with
CM03 intraperitoneally (ip) using the 15 mg/kg twice weekly
dosing regimen employed for the xenografts. While the median
survival between treated and untreated animals is similar, we
note that 3/7 mice survived much longer than all of the
untreated animals with two surviving more than twice as long
(Figure 2f).
CM03 Induces Down-Regulation of Genes Enriched in
G4s. CM03 is a potent G4 ligand, as shown by the FRET and
quantitative binding experiments reported here. We therefore
reasoned that the potent CM03 antiproliferative activity on
PDAC cells could be mediated through a G4-targeting
mechanism. To test this hypothesis, we determined whether
transcriptome changes upon early CM03 treatment were
correlated with G4 presence in promoters and/or gene bodies.
Two PDAC cell lines, PANC-1 and MIA PaCa-2 (both with
activating KRAS mutations), were treated for 6 or 24 h with
400 nM CM03 (1/10 of the calculated GI50 at 24 h, Supporting
Information, Figure 1a), RNA was harvested and gene
expression levels analyzed by RNA-Seq. The time and dose
of CM03 treatment were selected to reveal initial but robust
mRNA changes while minimizing chronic effects due to cell
toxicity. In both cell lines, the number of genes with altered
expression (as defined by >0.5 increase in Log 2 of fold change
[Log2 FC], or < −0.5 decrease; false discovery rate [FDR] <
0.1) increased with duration of CM03 treatment. In PANC-1
cells 2165 genes at 6 h and 3977 genes at 24 h were seen to
change, while in MIA PaCa-2 cells, 5306 genes changed at 6 h
and 5477 genes at 24 h compared to untreated controls
(Supporting Information, Table 1). Suggestive of a common
mechanism of action of CM03, the differentially expressed
genes were well correlated between the two cell lines at both
treatment times (6 h, r = 0.511; 24 h, r = 0.518) (Supporting
Information, Figure 1b−h) with 13044 expressed genes in
common (Supporting Information, Table 2) and a high number
of genes changed in both cell lines (1185 genes at 6 h, 1917
genes at 24 h). Remarkably, the differentially down-regulated
gene set (considering each cell line individually or combined)
was significantly enriched (p < 1 × 10−10) for putative G-
q u a d r u p l e x e s ( P Q s ) , a s d e fi n e d b y t h e
G≥3N1−7G≥3+N1−7G3≥N1−7G≥3 consensus sequence,
35,36 in
promoters and gene bodies at both 6 and 24 h treatments
compared to up-regulated or unaltered genes (cell lines
combined, Figure 3a,b; cell lines considered individually,
Supporting Information, Figures 2a,b and 3a,b). This
association was more marked for genes that were down-
regulated to the greatest extent by CM03 (Log2 FC ≤ 1.0, FDR
< 0.05) after 6 h treatment (down strong > down, ratio of
means) (Supporting Information, Table 3). To validate that the
targeting of G4-containing genes is not a general feature of
antiproliferative agents, we also examined the effects of the first-
line therapeutic agent for PDAC, gemcitabine,37 a potent
antiproliferative DNA synthesis inhibitor whose mechanism of
action is G4-independent and which remains a standard therapy
option in advanced PDAC. Both cell lines were treated with a
range of gemcitabine concentrations (Supporting Information,
Figure 4, Table 4) for 6 or 24 h. Crucially, no significant PQ
enrichment was observed for the down-regulated genes in any
gemcitabine condition (Supporting Information, Figures 2c,d
and 3c,d; 300 nM gemcitabine is shown as an example)). These
results strongly support the hypothesis that CM03 specifically
targets G4-bearing genes and represses their expression.
To gain insights into possible gene types and pathways
targeted by CM03, we performed a KEGG gene enrichment
pathway analysis of the common down-regulated genes. This
revealed a total of 11 and 46 significant pathways (p-EASE ≤
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0.05) after 6 and 24 h CM03 treatment, respectively. Many of
these pathways, or genes within them, have been previously
associated with PDAC (Figure 3c,d, Supporting Information,
Figures 5, 6; Tables 5, 6) such as axon guidance (14 genes, p =
5.75 × 10−5),7 the hippo signaling pathway (13 genes, p = 1.15
× 10−3)38 at 6 h, mTOR (12 genes, p = 1.07 × 10−4)39 and
VEGF signaling pathways (11 genes, p = 7.45 × 10−4)40 after
24 h and insulin resistance,41 and Rap1 and MAPK signaling
pathways across both time points40 (Figure 3e). This contrasts
with the pattern of the common up-regulated genes at 6 and 24
h (9 and 10 significant pathways, respectively) after CM03
treatment, with particular enrichment in cellular matrix
adhesion and major histocompatibility complex proteins
pathways (Supporting Information, Figure 7a). As anticipated,
300 nM gemcitabine treatment affected strikingly different
KEGG pathways compared to CM03 (Supporting Information,
Table 7). The most significant down-regulated gemcitabine
pathways (for both cell lines) were cell cycle after 6 h and
ribosome-associated pathways after 24 h, which is consistent
with its known mechanism of action in inhibiting DNA
synthesis, cell cycle progression, and global translation.37 This
contrasts with known pathways seen to be up-regulated after
gemcitabine treatment which includes the NF-Kappa B
signaling pathway (p = 1.61 × 10−6) for PANC-142 and the
Fanconi anemia pathway (p = 6.46 × 10−6) for MIA PaCa-2.43
It is notable that PQs in promoters and gene bodies are highly
enriched within down-regulated KEGG gene pathways after
CM03 treatment (Figures 3f, Supporting Information, Figure
7b) compared to random sampling across the expressed genes
or to up-regulated genes (Figure 3g and Supporting
Information, Figure 7c). Overall, these results robustly support
our contention that CM03 specifically targets critical pathways
that lead to pancreatic cell death via the inhibition of expression
gene sets harboring a G4 structure.
CM03 Treatment Results in an Increase in BG4 Foci
and DNA Damage. Because many established G4-stabilizing
ligands induce transcription and replication-coupled DNA
damage in the vicinity of G4-forming sequences,44 we
investigated whether CM03 treatment affects cellular G4
occurrence and/or induces a DNA damage response. To do
this, we treated asynchronous PANC-1 cells with CM03 and
performed immunofluorescence staining using the G4-specific
antibody BG418 and an antibody against the DNA damage and
double-strand break (DSB) marker 53BP145 followed by 3D
image construction and analysis. As predicted, 400 nM CM03
treatment resulted in a time-dependent significant (p < 0.05)
increase in the number of nuclear BG4 foci (Figure 4a,b) (393
± 13 at 6 h and 444 ± 39 BG4 foci at 24 h) compared to
Figure 4. CM03 treatment induces DNA damage and increases the presence of nuclear G4. (a) Following 6 and 24 h treatment with 400 nM CM03,
PANC-1 cells were fixed with paraformaldehyde and stained with antibodies against G4s (BG4, green) and the DNA damage marker 53BP1 (red).
Z-Stack images (11 μm × 0.3 μm spacing) were captured using a Nikon wide-field microscope and deconvolved using Hugyens Professional
software. The central slice of the Z-stack is shown in the representative images. White scale bar is 10 μm. Zoom panel represents increased
magnification of the highlighted section of the nucleus (dotted square) in the Merge panel. Yellow scale bar is 2.5 μm. Detection and co-localization
between BG4 and 53BP1 foci (white arrows) were performed using a custom protocol in the ICY software, which utilizes the spot detector and co-
localization studio plugins with the wavelet and Ripley’s K functions (see Methods). (b−e) The graphs show the mean number of (b) BG4 foci, (c)
53BP1 foci, (d) BG4-53BP1 co-localizations, or (e) percentage of total BG4 co-localizing with 53BP1 per nucleus with the standard deviation from
three biological replicates. A two-tailed Student’s t test was used to determine statistical significance across each condition (p < 0.05 = *, p < 0.01 =
**; n.s. = not significant). Each biological replicate represents 50−100 nuclei.
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Figure 5. Validation of mRNA down regulation by qRT-PCR for a subset of down-regulated genes, selected from RNA-Seq experiments. (a−d) MIA
PaCa-2 and PANC-1 cells were treated (a and b) with 400 nM CM03 and (c and d) with 400 nM gemcitabine, all for 6 and 24 h. Total mRNA was
extracted, reverse transcribed into cDNA, and then qRT-PCR was performed. The Ct values were normalized to the genomic mean of three
housekeeping genes (ACTB, GAPDH, and TUBB), and the relative gene expression was determined using the Livak method, 2−ΔΔCt. The log-fold
expression changes (Log2 FC) for each gene are shown relative to vehicle-treated controls (PBS for CM03 and DMSO for gemcitabine). Student’s t
test along with 2−ΔCt values were used to determine the statistical significance of the observed changes, which are the mean of in each case at least
three determinations. Those genes with changes in expression with p < 0.05 have been marked *.
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controls (297 ± 3 BG4 foci). This further confirms that CM03
has a direct action at G4 sites to increase G4 stabilization.
Consistent with the capability of unresolved endogenous
genomic G4 sites46 and small molecule-stabilized G4s to
obstruct DNA replication,44 a 2-fold increase in the number of
53BP1 foci was only apparent after 24 h treatment with CM03
(11 ± 2 compared to 21 ± 3 53BP1 foci) (Figure 4a,c). To
determine if CM03 induced DNA damage directly at G4 sites,
we calculated the extent of co-localization between BG4 and
53BP1 foci using object-based image co-localization analysis.
While the percentage of co-localization between BG4 and
53BP1 reproducibly increased by 50% after 24 h 400 nM CM03
treatment (Figure 4d), only 1.4% of total BG4 foci per nucleus
were associated with DNA damage foci (Figure 4e). Nonethe-
less, our data strongly suggests CM03 stabilizes G4 structures
leading to an accumulation of nuclear G4 foci accompanied by
the induction of DNA damage and replicative stress.
■ DISCUSSION AND CONCLUSIONS
While PDAC is predominantly (>95%) driven by oncogenic
KRAS,40 the development of more targeted therapies against
KRAS and other core PDAC associated pro-survival pathways
including: Ras-Raf-MEK-ERK and PI3K-AKt-mTOR have
proved futile owing to the highly mutagenic nature of the
disease5−8 and the ability of PDAC cells to rapidly switch
between phenotypic states, resulting in the evasion of therapy.47
As novel alternative strategies for intervention in PDAC are
urgently required, the targeting of G4s with small molecules has
been proposed as an innovative method for selective cancer
therapy.14 This is supported by recent G4-ChIP-seq and G4-IF
studies identifying an increased abundance of G4s in cancer
versus normal cells, as well as G4 structure enrichment at
oncogenes.16 We have recently reported that the G4 ligand
MM4133 reduces tumor volume by ∼80% in a PDAC xenograft
model. MM41 binds strongly to the G4s in the down-regulated
genes KRAS and BCL-2, resulting in cell apoptosis, and
suggested that G4 ligand treatment is potentially a highly
effective method for targeting PDAC. MM41 is a suboptimal
drug candidate due to its higher molecular weight and four
positive charges.32 We present here CM03 as an improved
rationally designed derivative of MM41 and as a novel lead
candidate compound for potential PDAC therapy in humans.
CM03 has comparable affinity for a human telomeric G4 to the
tetra-substituent compound MM41, indicating that the fourth
side chain and increased cationic charge on MM41 does not
make a major contribution to affinity. Although affinities for
CM03 or MM41 binding to (a single) G4 in vitro may be
difficult to directly relate to cell growth inhibitory properties,
CM03 is as potent in cells as MM41. Both compounds show
good selectivity for cancer cell lines (especially pancreatic) over
“normal” nononcogenic fibroblasts, but CM03 shows >4-fold
less activity toward the WI-38 cell line. This enhanced
selectivity is also apparent in vivo, where CM03 has a higher
level of tolerability (higher MTD) compared to MM41. This
suggests that the fourth side chain of MM41 may add to off-
target toxicity burden; however, neither MM41 nor CM03
show significant hERG liabilities (unpublished data), a common
indicator of cardiotoxic effects. The antitumor activity of CM03
results in sustained tumor growth arrest, which continues long
after dosing is ceased and compares favorably with the growth
delay typically seen with experimental antitumor agents.25 The
increased animal survival in a subset of the autochthonous KPC
mice to CM03 suggests that CM03 may be able to effectively
penetrate the tumor stroma microenvironment characteristic of
human PDAC.
The RNA-seq data revealed that treatment with CM03
resulted in a striking global differential down-regulation of
genes containing putative G4s (PQs), which occurred as early
as 6 h after treatment. We have performed RT-qPCR on a small
set of the genes down-regulated by CM03 (Figure 5a, b). The
results confirm the RNA-seq analyses: that these PDAC-
pathway genes are transcriptionally down-regulated in both cell
lines and that they are not significantly affected by gemcitabine
(Figure 5c,d). The RNA-seq results are consistent with the
hypothesis that G4 ligands can alter gene expression when PQs
are targets in individual genes.23 Previously, global G4-motif
specific changes in the transcriptome with bisquinolinium
compounds in HeLa cells have been reported using microarray
analysis.48 However, our work represents the first comprehen-
sive analysis using state-of-the-art RNA-seq methodology. This
is the first demonstration that a G4-binding small molecule
produces global down-regulation of G4-containing genes in
human cancer cell lines, in striking comparison with a non-G4
targeting drug, the modified nucleoside gemcitabine. Moreover,
as we identify G4 effects at much earlier times and smaller
doses than earlier studies, this further demonstrates that CM03
is a bona fide G4 ligand in cells and, by implication, in vivo as
well. The observed transcriptional effects of CM03 also align
with the hypothesis that down-regulation of gene expression is
mediated through ligand-stabilized G4s, causing for example
steric hindrance and inhibition of RNA pol II in the
transcription bubble (reviewed in ref 23). The observations
that transcriptional effects are closely aligned in two PDAC cell
lines, independently sequenced, gives added confidence to
these conclusions.
KEGG pathway analysis shows that CM03 targets 42
pathways, many of which are key to PDAC development and
maintenance. The most significant down-regulated pathways
after 6 h were the hippo signaling, axon guidance, and
endocytosis pathways, which are all deregulated in PDAC.
Hippo signaling acts through the core transcription factors,
YAP and TAZ. In PDAC, both YAP and TAZ are overex-
pressed and are essential for neoplastic progression.49 YAP/
TAZ also contributes to PDAC resistance to therapeutic
approaches directly targeting mutant KRAS.50,51 Notably,
CM03 down-regulates three prime effectors of YAP function,
TEAD2 and -4 (MIA PaCa-2 only) and TEAD3 (both cell
lines) at 6 h. As TEAD 2/4 are oncogenic in many cancers,52
CM03 may be suitable as a global cancer therapeutic agent.
CM03 also down-regulates the oncogenic Gli transcription
factors Gli2/4, downstream of TEAD and highly up regulated
in PDAC.6 As Gli2 is essential for KRAS-driven oncogenesis in
vivo53 and plays a role in PDAC resistance to both
gemcitabine54 and BET inhibitors,55 this suggests CM03 may
have a novel therapeutic potential.
For the axon guidance pathway, key PQs-containing genes
down-regulated by CM03 are PAK1,56 ROBO3,57 and
PLXNA1,58 all of which are highly overexpressed in PDAC.
While axon guidance is a neurodevelopmental process, many
axon guidance genes are deregulated in many cancers, including
PDAC, and contribute to metastasis and tumor growth.7,59
PAK1 mediates pancreatic cancer cell migration, growth,
promotes epithelial to mesenchymal transition (EMT), and is
crucial in conferring gemcitabine resistance.56 Expression of the
SLIT3 receptor, ROBO3, increases with PDAC clinical grade
and is anticorrelated with patient survival.7 As ROBO3
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promotes liver metastasis and tumor growth via Wnt signaling
pathway,59 this again suggests a more general CM03
therapeutic applicability. Likewise, the SEMA3A receptor,
PLXNA1, is up-regulated in PDAC and linked with poor
patient prognosis due to altered PLXNA1−SEMA3A signal-
ing.7,58
PDAC tumors experience hypoxia and nutrient deprivation
due to the dense surrounding tissue stroma, thus PDAC heavily
relies on endocytosis for scavenging of essential metabolites
and receptors/transporters recycling.60 A key endocytotic gene
ARF6, a member of the RAS superfamily of small GTPases
involved in plasma membrane trafficking, cell motility,
cytokinesis, and cholesterol homeostasis,61 is strikingly down-
regulated by CM03 (by 6 h). Mutant KRAS induces ARF6,
which acts as an oncogene in PDAC to drive the constitutive
activation of the ERK1/2 signaling and downstream effector
MYC, to regulate the Warburg effect.62 ARF6 has many other
roles including GLUT1 and CD95 receptor recycling,61
Table 1. RNA-Seq Expression Data for a Select Set of Down-Regulated Genes after CM03 Treatmenta
Log2 FC (6 h) Log2 FC (24 h) no. of PQs
gene symbol PANC-1
MIA
PaCa-2 PANC-1
MIA
PaCa-2 gene function
exons
and
introns promoter
AKT1 −0.18 −0.20 −1.04 −0.98 key protein kinase for (the AKT-mTOR signaling pathway: involved in
metabolism, proliferation, cell survival, growth, and angiogenesis
44 2
AKT1S1 −0.11 −0.54 −0.83 −1.09 subunit of mTORC1: regulates cell growth and survival in response to
nutrient and hormone signals
5 2
ARF6c −0.74 −0.89 −0.69 −0.54 RAS GTPase, protein trafficking, regulates endocytic recycling and
cytoskeleton remodelling, noncanonical EGRF, and hedgehog signaling
pathways
1 3
CBFA2T3b,c −2.18 −2.74 −2.25 −2.86 transcription regulator, HDAC pathways 96 4
CTBP1c −0.66 −0.52 −0.98 −1.17 transcriptional corepressor: oncogenic, required for PAK1-dependent
macropinocytosis
47 3
FASN −0.73 −0.06 −0.70 −0.54 fatty acid synthase 40 4
GLI1 0.03 −0.61 −0.57 −0.64 transcriptional activator, mediates hedgehog signaling 15 4
GLI2 −0.67 −1.17 0.38 −1.24 KRAS-driven oncogenesis, gemcitabine and BET inhibitor resistance,
effector of TEAD proteins, transcription regulator in hedgehog pathway
71 0
GLI4c −1.26 −1.71 −1.71 −1.85 up-regulated in PDAC, effector of TEAD proteins 11 0
IGF2 −1.15 −2.72 −1.53 0.72 insulin-like growth factor 34 8
IQSEC1c −0.86 −1.11 −0.50 −0.53 guanine nucleotide exchange factor for ARF1 and ARF6 82 5
MAPK11 −0.38 −0.53 −1.60 −2.56 essential effector kinase of p38 MAPK pathway 18 6
MAPK12 −0.75 −0.47 −1.44 −1.23 essential effector kinase of p38 MAPK pathway 18 6
MAPK9 −0.28 −0.09 −0.75 −0.60 essential effector kinase of JNK signaling pathway 10 3
mLST8c −0.54 −0.76 −1.72 −1.28 subunit of both mTORC1 and mTORC2 8 1
PAK1c −0.54 −0.59 −1.11 −1.13 protein kinase: involved in cancer cell migration and growth,
macropinocytosis, gemcitabine resistance
14 3
PARD6Ab,c −0.63 −0.83 −1.41 −1.40 tumour cell motility and metastatic potential 3 3
PCK2 −0.01 0.26 −0.56 −0.82 catalytic enzyme required for rate limiting step in gluconeogenesis 6 0
PFKFB4c −0.57 −1.02 −0.74 −0.93 glycolysis: synthesis and degradation of fructose 2,6-bisphosphate 10 2
PFKL −0 21 0.00 −0.98 −1.18 catalytic enzyme for first step of glycolysis 34 4
PIK3R2 −0.45 −0.55 −0.88 −1.14 regulatory subunit of PI3K 13 0
PIK3R3 −0.16 −0.28 −0.54 −1.47 binds to activated PI3K and regulates kinase activity 2 1
PLXNA1b,c −0.84 −0.98 −1.50 −1.56 receptor for class 3 semaphorins: involved in cancer invasion, migration,
and growth
54 3
PRDM16b,c −2.40 −2.73 −314 −3.39 transcription regulator: TGF8, SMAD pathways 260 5
PRKCZc −1.44 −1.87 −1.23 −2.01 cell polarity: PI3K, MAPK signaling pathway, NF-kappa-beta activation 78 3
ROBO3c −0.75 −0.86 −0.85 −0.53 axon guidance receptor, promoters liver metastasis through Wnt signaling,
expression increases with clinical grade of PDAC
19 3
RPTORc −0.80 −1.41 −0.50 −0 68 scaffold lor recruiting mTORC1 substrates 104 1
SHANK2b −1.65 −1.87 −0.44 −1.96 axon guidance, SRC pathways 203 4
SHC2c −0.52 −0.83 −1.47 −1.96 signaling adapter for insulin and VEGF signaling 41 8
SMO −0.92 −0.34 −0.82 −1.21 G protein-coupled receptor: transduces hedgehog signaling 12 1
TEAD2 −0.22 −0.65 0.21 −0.91 transcription factor, facilitates YAP interaction with DNA (Hippo
pathway)
19 10
TEAD3 −0.59 −1.06 0.07 −0.66 transcription factor, facilitates YAP interaction with DNA (Hippo
pathway)
29 7
TEAD4 −0.23 −0.79 −0.47 −0.31 transcription factor, facilitates YAP interaction with DNA (Hippo
pathway)
34 6
TP73b,c −1.44 −2.36 −0.99 −1.19 cell cycle, DNA repair regulation 91 5
ULK1 0.19 0.03 −0.81 −0.60 protein kinase autophagy: regulates formation of autophagosomes 38 6
aLog2 FC gene expression changes after 6 and 24 h CM03 treatment, the number of PQs and gene function are shown. Common down-regulated
genes are defined as having Log2 FC < 0.05 and FDR < 0.1 in both cell lines and genes are ranked by the lowest average Log2 FC.
bThe methylation
status of genes has been associated with patient survival (see Discussion). cGenes down-regulated (Log2 FC < 0.05, FDR < 0.1) in both cell lines at 6
and 24 h CM03 treatment.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01781
J. Med. Chem. 2018, 61, 2500−2517
2509
noncanonical EGRF and Hedgehog (Hh) signaling, and Hh-
mediated chemo-resistance.63 Furthermore, CM03 also targets
IQSEC1, a guanine nucleotide-exchange factor that is
responsible for activating ARF6 and whose down-regulation
inhibits PDAC invasion by preventing internalization of E-
cadherin from the plasma membrane.64 Other significant
pathways with CM03 down-regulated genes (at 24 h) involved
in altered PDAC metabolism include: fatty acid synthesis
(oncogene fatty acid synthase (FASN)),60 glycolysis (PCK2,
PFKL, and PFKFB4),65 autophagy (ULK1), and macro-
pinocytosis (PAK1 and CTBP1).66
Other key genes down-regulated by CM03 (by 6 h) which
also impinge on the above pathways include the binding
partners Par6 (PARD6A) and PRKCZ that are important for
tumor cell motility and metastatic potential in PDAC through
activation of JAK/STAT signaling pathway.67 Par6 also binds
PRKCi, another atypical protein kinase, which promotes PDAC
transformation partly through activation of the Rac1-MEK/
ERK signaling pathway.68 Of note, PARD6A knockdown
significantly reduces anchorage dependent growth and cell
invasion of both PRKCZ and PRKCi nonredundant path-
ways.67 The PKCi−Par6 complex also plays an oncogenic role
in lung, ovarian, and colon cancer.68 Together, this suggests
that CM03 could be effective in multiple cancer types. Other
CM03 down-regulated genes whose DNA methylation status
correlates with pancreatic cancer patient survival69 include
PRDM16 (rank 2), SHANK2 (rank 31), CBFA2T3 (rank 4),
and TP73 (rank 20) (at 6 h, Supporting Information, Table 2).
For PDACs driven by mutant KRAS, drug resistance
depends on a balance between PI3K/AKT/mTOR and
MAPK/ERK pathways and YAP1 and MYC up-regulation.70
It is striking that CM03 treatment down regulates many
elements of this mechanism (see Table 1). For example AKT
(AKT1), key effectors of mTOR (RPTOR, mLST8, AKT1S1),
PI3K pathway (PIK3R3 and PIK3R2) and MAPK proteins
(MAPK9, MAPK11, and MAPK12) are down-regulated in both
PDAC cell lines by CM03 (by 24 h). In the noncanonical Hh-
mediated gemcitabine resistance pathway the transcript levels
of SMO and GLI1 are also down-regulated by CM03.54 Tumor
associated macrophages and cancer-associated myofibroblasts
in tissue stroma are also key drivers for chemoresistance in
PDAC, and it is notable that IGF2 and SHC2 are down-
regulated by CM03 as these proteins have been implicated in
insulin receptor-mediated chemoresistance.71 Collectively,
these findings clearly demonstrate the ability of CM03 to
simultaneously target several fundamental PDAC tumorigenesis
mechanisms.
Curiously, while CM03 shows binding affinity to KRAS G4s
in vitro (Figure 1e), our RNA-SEQ studies show that KRAS
mRNA expression is unaffected by CM03 treatment in either
pancreatic cell line at the times and doses tested (Supporting
Information, Table 1). It may be that in a cellular context the
KRAS G4 is rapidly resolved by unwinding helicases or that G4
binding proteins hinder drug accessibility. Thus, while the
KRAS G4s may not be the main/initial target of CM03, we
cannot assume the accessibility of KRAS G4 for CM03 within
the native epigenetic environment. Nonetheless, our results
suggests that simultaneous targeting of multiple fundamental
PDAC pathways (including important KRAS effector and
feedback loop signaling pathways and those involved in drug
resistance) by G4 stabilization will be an advantageous
approach.
CM03 also resulted in the induction of DNA damage in a
replication-dependent manner. While the number of BG4 foci
increased upon CM03 treatment suggesting increased G4
stabilization, only a small increase in BG4 and 53BP1 co-
localization was observed. It is tempting to suggest that CM03
does not cause an increase in damage at G4 sites, however, the
dynamics of whether a G4 structure can co-exist with DNA
damage response proteins is not well understood or whether
G4s persist after DNA damage response and repair have been
elicited. In support, many DNA repair pathway proteins are
capable of unwinding and destabilizing G4,72 and a recent study
has elucidated the role of PARP3 negatively regulating G4 in
order to initiate DNA repair at DSB sites.73 Hence, by 24 h, the
small number of co-localizations could represent an inter-
mediate repair state of DNA at a G4 site.
In summary, we have demonstrated that CM03 is a highly
potent G4-binding small molecule, with in vitro cell assays and
in vivo models for human PDAC. Treatment with CM03
successfully reduced tumor growth for an extended period in
PDAC xenografts and also prolonged survival in the KPC
mouse model for this disease at dosage levels that do not cause
observable damage to major organs yet enable selective tumor
targeting. It is notable that the antitumor effects of CM03 in the
xenograft model persisted until the termination of the
experiment at day 62 (34 days beyond the end of dosing).
This is in striking contrast to the antitumor response to
gemcitabine, with tumor regrowth being apparent as soon as
dosing was stopped.
Studies with PDAC cell lines suggest that the mechanism of
action of CM03 is via the G4-dependent down-regulation of
genes in a number of essential pathways associated with PDAC
survival, metastasis, and drug resistance, together with the
activation of G4 replication-dependent DNA damage. Fur-
thermore, given the good bioavailability of CM03 and its ability
to target many oncogenic pathways essential to tumorigenesis
in general, we suggest that CM03 has the potential to be used
as an effective anticancer therapeutic in a number of other
cancers in addition to PDAC. It is tempting to speculate that
the selective tumor targeting is associated with G4 binding, and
future studies will address this question.
■ EXPERIMENTAL METHODS
Chemistry. The synthesis and characterization of MM41 (4,9-
b is((3-(4-methylp iperaz in-1-y l)propyl)amino)-2 ,7-b is(3-
morpholinopropyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-
tetraone: molecular weight 831.08) has been previously reported.32a
MM41 was analytically pure as shown by LC-MS and NMR methods
and was formulated for biological studies as the freely water-soluble
formate salt.
The traditional synthetic route to highly substituted naphthalene
diimides starts from 1,4,5,8-naphthalene tetracarboxylic dianhydride,
which is then reacted with dibromoisocyanuric acid, leading to the
mono- and dibromonaphthalene diimide as key intermediates,
followed by introduction of the amine chains at the imide and bay
positions, in that order. This synthesis results in a complex mixture
requiring purification by preparative HPLC at least twice to obtain the
desired products in very low yield (less than 10%). The critical aspect
of the present synthetic scheme was preparation of the monobromi-
nated naphthalene diimide precursor; this is insoluble, so purification
at this stage was not attempted, nor was there any evaluation of the
amount of monobromo derivative obtained. Purification can be
performed only after the N−N′ imidation reaction due to the aqueous
solubility that is imparted by the introduction of the basic morpholino
side chains. Instead, the procedure was modified as shown in Scheme
1.
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All chemicals, reagents, and solvents were purchased from Sigma-
Aldrich, Alfa Aesar, Lancaster Synthesis, and Fluorochem (UK) and
used without further purification. Solvents were supplied by VWR and
Fisher Scientific. Column chromatography was performed using BDH
silica gel (BDH 153325P). Chromatography was conducted under
medium pressure in glass columns or using a Biotage SP4 instrument
in prepacked columns (FLASH Silica columns (40−63 μm, 60 Å)).
HPLC analysis was carried out with a Gilson apparatus combining a
322 pump and an Agilent 1100 series detector, using a C18 5 μ (100
mm × 4.6 mm) column (41622271 (W), YMC, Japan) at a flow of 1
mL/min. Preparative HPLC was carried out with a Gilson apparatus
combining a 322 pump and a UV/vis-155 detector with detection at
280 nm, using a C18 5 μ (100 mm × 20 mm) column (201022272)
(W), YMC, Japan, at a flow of 20 mL/min. Water and methanol with
0.1% formic acid were used as solvents for HPLC. For the purification
of compound CM03, the following method was used: 100% aqueous
solution for 5 min after injection, then gradually decreased to 60%
aqueous solution over 25 min.
2-Bromo-1,4,5,8-naphthalenetetracarboxylic Acid Dianhydride
(2a) and 2,6-Dibromo-1,4,5,8-naphthalenetetracarboxylic Acid
Dianhydride (2b). Naphthalene dianhydride (1, from Sigma-Aldrich)
(150 mg, 0.56 mmol) was slurried in sulfuric acid (1.5 mL), and the
suspension obtained was stirred for 5 min at room temperature to
allow the complete dissolution. 5,5-Dimethyl-1,3-dibromohydantoin
(88 mg, 0.308 mmol) was added slowly over a period of 1 h, and the
round-bottom flask was tightly stopped to avoid the escape of bromine
from the reaction mixture. The solution was stirred at 80 °C for 72 h
and then poured onto ice (30 mL). The yellow solid formed was
filtered, washed with water (2 × 10 mL), and dried under vacuum,
yielding a mixture 2a and 2b. No NMR data were obtained due to
solubility issues. The resulting mixture was used without further
purification in the next step.
N,N′-Bis(3-(morpholino)propylamino)-2-bromo-1,4,5,8-naphtha-
lenetetracarboxylic Acid Diimide (3a). Compounds 2a and 2b (194
mg, 0.56 mmol) were suspended with sonication in glacial acetic acid
(1.5 mL) in a microwave reaction vessel. 3-Morpholinopropyalamine
(242 mg, 245 μL, 1.68 mmol) was added dropwise to the stirring
mixture. The reaction tube was sealed and treated for 30 min at 125
°C in the microwave. The solution was then basified with potassium
carbonate and extracted with chloroform (3 × 5 mL). The organic
phases were collected, dried over sodium sulfate, and evaporated. The
residue obtained was purified through column chromatography using
as eluent a CH2Cl2/MeOH 96/40 mixture. Yield 3a (107 mg, 0.18
mmol, 35%). 1H NMR (CDCl3) δ 1.95−1.97 (m, 4H), 2.40−2.43 (m,
8H), 2.52−2.53 (m, 4H), 3.51−3.54 (m, 8H), 4.28−4.33 (q, 4H, J = 8
Hz), 8.77 (d, 1H, J = 8 Hz), 8.82 (d, 1H, J = 7.6 Hz), 8.935 (s, 1H).
13C NMR (100 MHz, CDCl3, TMS) δ 23.31, 23.44, 38.81, 39.11,
52.50, 55.51, 55.45, 65.37, 65.41, 123.97, 125.75, 125.95 (2C), 126.01,
126.84, 128.68, 128.76, 130.73, 131.71, 138.44, 161.17, 161.87, 161.98,
162.56. HRMS (ES+) calculated C28H33BrN4O6 [M + 2H]
+ 600.1543,
found 600.1536.
2,7-Bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)-
benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (Com-
pound 4: CM03). Compound 3a (0.15 g, 0.25 mmol), 1-(2-
aminoethyl)pyrrolidine (0.06 mL, 0.51 mmol), and NMP (1 mL)
were suspended in a microwave reaction vessel. The reaction tube was
sealed and treated for 25 min at 130 °C in the microwave. After having
been cooled to room temperature, the solvent was concentrated and
the crude mixture was purified by column chromatography, using as
eluent a mixture of CH2Cl2/MeOH/NH3 95/5/0.4. Compound 4 was
obtained as a red oil (118 mg, 0.186 mmol, 75% yield). 1H NMR (400
MHz, CDCl3, TMS) δ 2.019−2.040 (m, 8H), 2.683−2.782 (m, 12H),
3.195 (t, 4H, J = 6.4 Hz), 3.32 (t, 2H, J = 6.6 Hz), 3.708 (t, 4H, J = 4.8
Hz), 3.764 (t, 4H, J = 4.6 Hz), 4.009−4.024 (m, 2H), 4.22 (t, 4H, J =
7 Hz), 8.237 (s, 1H), 8.28 (d, 1H, J = 7.6 Hz), 8.56 (d, 1H, J = 8 Hz),
10.174 (t, 1H, exch D2O, J = 4.2 Hz).
13C NMR (100 MHz, CDCl3) δ
23.3, 23.6, 23.7, 38.2, 38.9, 40.1, 52.6, 52.8, 53.9, 53.9, 55.8 (2C), 65.6,
65.8, 100.7, 119.1, 119.5, 123.5, 124.9, 126.1, 128.0, 129.2, 131.4,
151.8, 162.8, 163.2, 165.9, 166.5. HRMS (ES+) calculated for (M +
H)+ C34H45N6O6 633.3389, found 633.3401. For the HPLC purity
analysis of this compound, the method used was: 100% aqueous
solution for 5 min after injection, to 60% w/v aqueous solution over
18 min as well as 100% aqueous for 5 min after injection, to 60% w/v
aqueous over 43 min. The purity for the final compound was greater
than 95% (HPLC, 280 nm) and was further checked by LC-MS.
CM03 was then converted to a mixed hydrochloride/formate salt in
order to enhance its aqueous solubility. At a concentration of 5 mg/
mL, the pH of the CM03 salt solution was 6.95.
Molecular Modeling. The crystal structure of the naphthalene
diimide intramolecular telomeric G4 complexes32,74 (PDB 2T5E,
4DA3, and 3UYH) were used as starting points to study G4−ligand
interactions, in particular that with the compound MM41.32a The
structure of the native human intramolecular DNA quadruplex with
parallel-stranded propeller-type topology was extracted from the
Protein Data Bank (www.rscb.org) and used for docking with CM03.
The final structures were subjected to 1000 steps of conjugate gradient
energy minimization to relieve any structural distortions.
The docking protocol was consistent for all systems. The chemical
structures of the ligands MM41 and CM03 were sketched, built, and
docked using ICM-Pro software (www.molsoft.com). Atom-centered
charges were assigned using the ICFF force field.75 Grid maps were
made that encompassed the terminal quartets, central K+ ions, and the
loops. Docking was done using the automated docking module in the
ICM-Pro package, employing the default parameters. The final docked
conformations were chosen based on the strongest binding energy
between the docked ligands and the G4. The grids were large enough
to allow translation and rotation of the ligands. The top 20 plausible
conformations of the ligands were then analyzed. The final docked
models were chosen based on the largest interaction energy between
G4 and ligand. The positively charged ions were retained within the
central axis of the G4 channel and were treated as an integral part of
the G4 structure.
FRET Studies. FRET DNA melting assays on MM41 and CM03
were performed using a fluorescence resonance energy transfer
(FRET) assay.76 The labeled oligonucleotides had the fluorophores
6-carboxyfluorescein (FAM) as donor and fluorophore 6-carboxyte-
tramethyl-rhodamine (TAMRA) attached as acceptor. The sequences
used are
Human telomeric G4 (F21T): 5′-FAM-d(GGG[TTAGGG]3)-
TAMRA-3′.
Duplex sequence 5′-FAM-d(TATAGCTATA-HEG-TATAGC-
TATA)-TAMRA-3′ (HEG linker, [(−CH2-CH2-O−)6])).
HSP90a: 5′-FAM-d(GGGCCAAAGGGAAGGGGTGGG)-
TAMRA-3′.
HSP90b: 5′-FAM-d(GGGCGGGCCAAAGGGAAGGGG)-
TAMRA-3′.
Kras21: 5′-FAM-d(AGGGCGGTGTGGGAAGAGGGA)-TAMRA-
3′.
Kras32: 5′-FAM-d(AGGGCGGTGTGGGAAGAGGGAAGA-
GGGGGAGG)-TAMRA-3′.
Bcl-2: 5′-FAM-d(GGGCGCGGGAGGAAGGGGGCGGG)-
TAMRA-3′.
The FRET probe sequences were diluted from stock to the correct
concentration (400 nM) in a 60 mM potassium cacodylate buffer (pH
7.4) and then annealed by heating to 95 °C for 10 min, followed by
cooling to RT in a heating block (3−3.5 h). Drug stock solutions (at
2× concentration) were prepared using 60 mM potassium cacodylate
buffer (pH 7.4). Then 96-well plates (MJ Research, Waltham, MA)
were prepared by aliquoting 50 μL of annealed DNA into each well,
followed by 50 μL of the compound solutions. Measurements were
made on a DNA Opticon Engine (MJ Research) with excitation at
450−495 nm and detection at 515−545 nm. Fluorescence readings
were taken at intervals of 0.5 °C in the range 30−100 °C, with a
constant temperature being maintained for 30 s prior to each reading
to ensure a stable value. Final analysis of the data was carried out using
a script written in the Origin 7.0 (OriginLab Corp., Northampton,
MA) package and its advanced curve-fitting function for derivation of
ΔTm values.
Quantitative G4 Binding Studies. Human telomeric DNA G4
was prepared using oligonucleotides purchased from Integrated DNA
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Technologies (Coralville, IA, USA). The DNA purity and sequence
was verified by mass spectrometry. Desalted oligonucleotide sequences
were initially suspended in 150 mM NH4OAc (pH 6.8) in nuclease-
free water to yield a final concentration of 1 mM and determined
spectroscopically at 260 nm using the nearest-neighbor method. The
stock solution was aliquoted into 20 μL samples in 200 μL PCR tubes.
Using a thermocycler, samples were heated to 98 °C for 10 min, slowly
cooled for 15 min while remaining within the thermocycler, followed
by an additional cooling session at RT for 30 min, and stored at 4 °C
before use.
Fluorescence anisotropy measurements were obtained on a Variant
Cary Eclipse fluorescence spectrophotometer (Agilent Technologies,
Santa Clara, CA, USA) equipped with a polarization attachment. The
excitation and emission polarizers were fixed between the light source
and detector, respectively. Measurements were converted into
anisotropy values by using eqs 1 and 2:
= − ×
+ × ×
r
I I
I I
GF
2 GF
vv vh
vv vh (1)
= I
I
GF hv
hh (2)
r is the anisotropy value, Ivv is the fluorescence intensity of the
samples when excitation and emission polarizers are aligned in vertical
positions, Ivh is the fluorescence intensity of the samples when the
excitation and emission polarizers are in vertical and horizontal
positions, respectively, Ihv is the fluorescence intensity of compound
when excitation and emission polarizers are aligned in horizontal and
vertical positions, Ivv is the fluorescence intensity of compound when
excitation and emission polarizers are aligned in vertical positions, and
GF is the grating factor of the polarizers. The GF value was introduced
to the equation to correct for unequal sensitivity of the excitation and
emission polarizers.77
To determine dissociation constants, MM41 was added to a 3 mL
volume of the experimental buffer (50 mM KCl, 10 mM Tris-HCl, 1
mM EDTA in nuclease-free water at 25 °C, pH 7.3) in a quartz
fluorescence cuvette at a fixed concentration of 50 nM, and G4 was
titrated into the cuvette. Oligonucleotide concentrations were
calculated before each titration experiment and fluorophore concen-
trations corrected after each addition by taking dilution into account.
Measurements were taken at a maximum emission wavelength of
MM41 (λem = 670 nm) with excitation at λex = 630 nm. Both
excitation and emission slits were at 20 nm. Each set of measurements
were taken from a 50 s average reading measurement (PMT = 630 V).
The dissociation constant (KD) of MM41 to G4 was obtained by
fitting the change in anisotropy value of the compound titration using
the following equation:
= + − + +
− + + −
r r r r K L D
K L D LD L
[( ){
( ) 4 /2 }]
observed min max min D
D
2
(3)
rmin is the anisotropy value of free MM41, rmax is the anisotropy
value of bound MM41, L is the total concentration of MM41, and D is
the total concentration of G4.77
Direct fluorescence measurements were performed using the same
instrument and experimental buffer. Both emission and excitation slits
were set to 20 nm. Fluorescence was measured in a quartz fluorescence
cuvette with a starting CM03 concentration of 25 nM. The amount of
oligonucleotide needed for the experiment was calculated and titrated
into the cuvette. Changes in maximum emission intensity of CM03
(λem = 570 nm) were observed and recorded upon binding to
telomeric DNA. The curve fit equation is similar to eq 3, taking into
account that fluorescence intensity values decrease upon titration
(initial intensity > final intensity). The results were fitted to obtain a
dissociation constant (KD) using the fluorescence quenching equation
below:
= − − + +
− + + −
A A A A K L D
K L D LD L
[( ){
( ) 4 /2 }]
Dinitial initial final
D
2
(4)
Ainitial is the intensity measured for free CM03, Afinal is the intensity
measured of bound CM03, KD is the dissociation constant of the
complex, L is the total concentration of CM03, and D is total
concentration of G4.
Cell Culture Studies. All cell lines were purchased from ATCC
and maintained in appropriate medium supplemented with 10% fetal
bovine serum (Invitrogen, UK), 2 mM L-glutamine (Invitrogen,
Netherlands), and other components as specified by the suppliers. Cell
lines were maintained at 37 °C, 5% CO2, and routinely passaged.
Drugs were dissolved in H2O and filtered through 0.22 μm pore-size
filter units (stock 10 mM) before addition to appropriate cell line
media. Cellular growth inhibition was measured using the sulforhod-
amine B (SRB) assay in 96-well plates as described previously.78 The
50% inhibitory concentrations (IC50) were determined by taking the
mean absorbance at 540 nm for each drug concentration expressed as
a percentage of the absorbance of untreated control wells.
Xenograft Studies. All animal experiments were performed in
accordance with the UK Home Office Animals Scientific Procedures
Act 1986 and the United Kingdom Coordinating Committee on
Cancer Research Guidelines for the Welfare and Use of Animals in
Cancer Research79 and with the approval of the University College
London Animal Ethics Committee. Mice had access to food and water
ad libitum.
The maximum tolerated dose (MTD) studies of MM41 and CM03
were performed in CD-1 nude mice. The MTD of a single dose
administered intravenously (IV) was examined, and repeat dosing was
performed per week at different concentrations of MM41 (20, 25, and
30 mg/kg) and CM03 (10, 20, 30, 35, 40, 45, 50, and 60 mg/kg), with
two mice per group. Compounds were administered in saline. Mice
were monitored visually for signs of adverse effects over periods of up
to 72 h. The maximum tolerated dose was judged to have been
reached when all mice in a particular dose cohort survived in the
absence of any observed ill effects for the period of the experiment.
For therapy studies, female CD-1 nude mice (2−3 months old,
weighing 20−25 g) were injected subcutaneously with 5 × 106 MIA
PaCa-2 cells in the right flank (unsupplemented RPMI + Matrigel).
When the tumors were established (approximately 13 days, mean size
0.05 cm3), the mice were divided into five treatment groups with eight
mice/group. The MM41 and CM03 samples were dissolved directly in
saline to the required concentrations and administered IV. Tumor size
was measured weekly by calliper using the π-based ellipsoid volume
formula (length × width × height × π/6) every 3−4 days, and the
mice were also weighed and examined at the same time to determine
any signs of toxicity from the drug.
Group 1:15 mg/kg of gemcitabine (Sigma), twice weekly dose.
Group 2:15 mg/kg of MM41, twice weekly dose.
Group 3:10 mg/kg of CM03, twice weekly dose.
Group 4:15 mg/kg of CM03, twice weekly dose.
Group 5: saline only, twice weekly dose.
The xenograft data was analyzed using Student’s t test (GraphPad
Inc.). Responses were considered to be significant for those with
probabilities (p) less than 5% (p < 0.05). Mice were culled if there was
any sign of tumor ulceration, if tumor volume exceeded 1.5 cm3, or if a
weight loss over 20% of initial body weight was observed. Samples of
liver, kidney, and spleen from each animal in the CM03 (15 mg/kg)
and untreated control groups were excised at the end of the therapy
experiment, then fixed in 10% neutral buffered formalin for at least 48
h prior to processing and paraffin embedding. Tissue slices were
stained with hematoxylin and eosin and assessed visually for any
obvious differences compared with controls, indicative of toxicity and
tissue damage. For the imaging study mice were anesthetized using
isoflurane and imaged using the IVIS preclinical imaging system from
PerkinElmer. Images were captured after 4 h following intravenous
administration of CM03 using Cy5.5 excitation for 5 s.
KPC Mouse Model. KPC (Pdx1-Cre; LSL-KrasG12D/+; LSL-
Trp53R172H/+) mice were described previously.80 Mice on a mixed
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background were bred in-house and maintained in conventional caging
with environmental enrichment, access to standard chow, and water ad
libitum. Genotyping was performed by Transnetyx (Cordoba, TN,
USA). Mice were monitored three times weekly and randomized to
receive either 15 mg/kg of CM03, or saline control IP, twice weekly
when exhibiting symptoms of PDAC (swollen abdomen, loss of body
conditioning resembling cachexia, reduced mobility). Pancreatic
malignancy was confirmed by abdominal palpation. Mice were culled
by schedule 1 method when symptoms progressed. All animal
experiments were performed under a UK Home Office license and
approved by the University of Glasgow Animal Welfare and Ethical
Review Board.
RNA-seq Studies. RNA-seq analyses of exposure to CM03 were
undertaken at Cambridge with PANC-1 cells and at UCL with MIA
PaCa-2 cells. Data merging and subsequent analyses were undertaken
in Cambridge.
Cell Culture. The PDAC cell lines PANC-1 (ATCC, catalogue no.
CRL-1469) and MIA PaCa-2 (ATCC, catalogue no. CRL-142) were
maintained in DMEM (ThermoFisher, catalogue no. 11965092)
supplemented with 10% (v/v) heat inactivated FBS (ThermoFisher)
in a humidified atmosphere containing 5% CO2 at 37 °C. Cell lines
were confirmed mycoplasma free by RNA-capture ELISA, and their
genotypes were certified by STR profiling.
Determination of CM03 and Gemcitabine Dosage for RNA-Seq.
PANC-1 and MIA PaCa-2 cell lines were seeded overnight at 3 × 103
cells/well and 2 × 103 cells/well in 96-well plates, respectively. Next
morning, cells were treated with 0−10 μM CM03 (stock 10 mM in
dH20) for 24 h. For treatment with gemcitabine-HCl (Tocris,
catalogue no. 3259) (stock 50 mM in DMSO), cells were treated
with 0−5 mM for 24, 48, 72, and 96 h. Cells were then incubated with
100 μL/well of CellTiter-Glo One Solution Assay reagent (Promega,
catalogue no. G8461) for 30 min at RT, and luminescence was
measured using a PHERAstar FS microplate reader (BMG LabTech).
Cell survival curves were then plotted and GI50 values were calculated
using GraphPad Prism version 6.00 (GraphPad Software Inc.). Error
bars represent standard deviation of the mean of four technical
replicates.
RNA-seq. PANC-1 (0.35 × 106 cells/well) and MIA PaCa-2 (1.5 ×
106 cells/well) cell lines were seeded overnight in 60 mm plates. Next
day, cells were treated with 400 nM CM03 for 6 and 24 h. For
gemcitabine treatment, cells were treated for 6 and 24 h with DMSO
or 30 nM, 100 nM, 300 nM, 1 μM, 3 μM, and 10 μM gemcitabine-
HCL for PANC-1 cells and 30 nM, 300 nM, and 3 μM gemcitabine-
HCl for MIA PaCa-2 cells. Total RNA was extracted using the Qiagen
RNeasy Plus Mini Kit (ThermoFisher, catalogue no. 74134) as per the
manufacturer’s instructions. RNA quality (RIN > 9.0) was checked
with an Aligent 2100 bioanalyzer RNA 6000 Nano Chip, and RNA
concentration was quantified using a Qubit fluorometer (Thermo-
Fisher) and Qubit RNA HS Assay Kit (Qiagen, catalogue no.
Q32852). RNA-seq libraries were then generated using the Illumina
Truseq RNA HT (stranded mRNA) kit (Illumina, catalogue no. RS-
122−2103) as per the manufacturer’s instructions and sequenced
using an Illumina HiSeq4000.
RNA-Seq Analysis. Fastq raw sequencing files were preprocessed
using cutadapt81 to remove sequencing adapters and low quality
sequencing tails (options −q 10) and then aligned to the human
genome (GRCh37/hg19) using tophat282 and using the UCSC gtf file
provided by Illumina iGenomes as an annotation file (http://support.
illumina.com/sequencing/sequencing_software/igenome.html). Gene
counts were calculated using htseq-count83 and the same gtf file.
Differential expression analysis was done using the R package edgeR.84
Differentially expressed genes were estimated independently for both
cell lines (MIA PaCa-2 and PANC-1) and for the different time points
(6 and 24 h) and were then intersected to inspect the common genes.
The sequencing data is available at the GEO public functional
genomics data repository (https://www.ncbi.nlm.nih.gov/geo/) as
GSE105083. Details of the putative G4 sequence (PQs) analysis are
given in the Supporting Information.
Immunofluorescence Microscopy. BG4 and 53BP1 immuno-
fluorescence experiments were performed essentially as described,16,18
with slight modifications. In brief, 8 × 104 PANC-1 cells were seeded
overnight on circular no. 1.5 coverslips per well in 12-well plates. Next
day, cells were incubated with 400 nM CM03 (or left untreated) in 1
mL of media at 37 °C for 6 and 24 h and then fixed with 4 (v/v) %
freshly prepared paraformaldehyde in 1× PBS for 10 min at RT.
Coverslips were washed 1× PBS, permeabilized with 0.1% (v/v)
Triton-X100 in PBS for 10 min, washed with 1× PBS, and blocked
with 2% (w/v) Marvel milk (Premier Foods plc) in PBS for 1 h at 37
°C. After blocking, coverslips were incubated with BG4 (20 nM) at 37
°C for 1 h, washed three times for 5 min with PBST (0.1% (v/v)
Tween 20), and then incubated with 37 °C for 1 h with rabbit α-FLAG
1:800 (CST, catalogue no. 2368) and mouse α-53BP1 1:500
(Millipore, catalogue no. MAB2803). Subsequently, all coverslips
were washed as described and incubated for 30 min at 37 °C with goat
α-rabbit Alexa-488 (Thermofisher, catalogue no. A-11034) and goat α-
mouse Alexa-647 (ThermoFisher, catalogue no. A-21236) at 1:800
dilution. DAPI nuclear counterstain was included in the final antibody
incubation. Coverslips were then rinsed three times with reverse
osmosis grade water, air-dried, and mounted onto Superfrost Plus
slides (ThermoFisher, catalogue no. 4951PLUS) with ProLong
Diamond Antifade Mountant (Invitrogen, catalogue no. P36961).
Three biological replicates were performed. Z-Stack images (11 steps,
0.3 μm apart) were acquired on a Nikon Eclipse TE2000E inverted
microscope with a Nikon Plan Apo λ 100× NA 1.45 oil DIC H
immersion objective using an Andor Neo SCC-00488 camera at 0.06
μm per pixel. Fluorescence illumination was with a xenon source and
FITC, Cy5, and DAPI fluorescent filter cubes used to image BG4,
53BP1, and the nuclei, respectively. Then 10−12 Z-stacks were taken
per replica representing approximately 50−100 nuclei. Images were
deconvolved using Huygens Professional Software (Scientific Volume
Imaging BV). See extended methods, immunofluorescence, for the
custom protocol designed for the BG4-53BP1 foci quantification and
co-localization method.
RT-qPCR Studies. MIA PaCa-2 (6 h = 2.5 × 106 and 24 h = 1.0 ×
106 cells/well) and PANC-1 (6 h = 1.0 × 106 and 24 h = 0.5 × 106
cells/well) cell lines were seeded in 100 mm plates and incubated
overnight. In the following day, cells were treated with 400 nM CM03,
400 nM gemcitabine, PBS, or DMSO for 6 and 24 h. Total RNA was
extracted from 2−4 × 106 cells using the RNeasy mini kit (Qiagen,
catalogue no. 74104), and on-column DNaseI digestion (Qiagen,
catalogue no. 79254) was performed to remove residual genomic
DNA. The concentration of harvested RNA was measured with a
NanoDrop 2000/2000c spectrophotometer (ThermoFisher). The
required amount of RNA was reverse transcribed into cDNA using a
SuperScript III First-Strand Synthesis System (ThermoFisher,
catalogue no. 18080051) following the manufacturer’s instructions.
RT-qPCR was performed using Power SYBR Green Master Mix
(ThermoFisher, catalogue no. 4368706) with a 50 ng template and
150 nM primers in an AriaMx Realtime PCR System (Agilent).
Primers were purchased from Eurofins Genomics or from Sigma
(KiCqStart SYBR Green Primers). Data was derived from three or
four independent experiments, each performed in triplicate. The Ct
values were normalized to the genomic mean of three housekeeping
genes ACTB, GAPDH, and TUBB, and the fold change was
determined using 2−ΔΔCt.
Ancillary Data. The sequencing data is available at the GEO public
functional genomics data repository (https://www.ncbi.nlm.nih.gov/
geo/), as GSE105083. The PDB files for the “best” molecular models
of MM41 and CM03 with the human DNA telomeric quadruplex are
available as Supporting Information.
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